Model predicts death due to acetaminophen overdose

February 24, 2012 in Medications

Model predicts death due to acetaminophen overdose

Model for Acetaminophen-induced Liver Damage, a mathematical model that utilizes commonly obtained laboratory values, including overdose amount and time elapsed since overdose, is effective for predicting outcomes in patients with acute liver failure due to acetaminophen overdose, according to research published online Feb. 13 in Hepatology.

(HealthDay) -- Model for Acetaminophen-induced Liver Damage (MALD), a mathematical model that utilizes commonly obtained laboratory values, including overdose amount and time elapsed since overdose, is effective for predicting outcomes in patients with acute liver failure due to acetaminophen overdose, according to research published online Feb. 13 in Hepatology.

Christopher H. Remien, of the University of Utah in Salt Lake City, and colleagues developed MALD to describe acute due to an overdose of acetaminophen. The model utilizes laboratory values that are commonly obtained on admission, specifically aspartate aminotransferase (AST), alanine aminotransferase (ALT), and international normalized ratio (INR), to estimate the overdose amount, time elapsed, and outcome. The model was tested on 53 patients.

The researchers found that, using only initial ALT, AST, and INR measurements, the model was able to accurately predict follow-up laboratory values for most patients. With the addition of , the researchers were able to predict eventual death due to acetaminophen overdose with 100 percent sensitivity, 91 percent specificity, 67 percent , and 100 percent negative predictive value.

"Our dynamic model yields a prediction of outcome by estimating the time since overdose and overdose amount from commonly obtained laboratory data on admission," the authors write. "Our initial analysis suggests that MALD compares favorably to statistical methods, and should be validated in multicentric retrospective and prospective evaluation."

More information: Abstract
Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts

More news stories

Merck ends development of Parkinson's disease drug

(AP)—Merck & Co. says it is ending development of an experimental Parkinson's disease drug because the drug wasn't working.

Medications created May 23, 2013 | popularity 1 / 5 (1) | comments 0

J&J expects 10-plus new drug applications by 2017

(AP)—Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during ...

Medications created May 23, 2013 | popularity 5 / 5 (1) | comments 0

Experts favor US approval of Merck sleeping pill (Update)

An independent panel of experts on Wednesday recommended US approval of a new Merck sleeping pill called suvorexant, but expressed concerns over the highest dosage and risks of drowsy daytime driving.

Medications created May 22, 2013 | popularity not rated yet | comments 0

Glaxo, US partnering to develop new antibiotics

GlaxoSmithKline PLC says it's starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and bacterial infections resistant to current medicines.

Medications created May 22, 2013 | popularity not rated yet | comments 0

Study finds new pneumococcal vaccine appears to be as safe as previously used vaccine

The new 13-valent pneumococcal conjugate vaccine (PCV13) appears to be as safe as the previous version used prior to 2010, the 7-valent pneumococcal conjugate vaccine (PCV7), according to a Kaiser Permanente study published ...

Medications created May 22, 2013 | popularity not rated yet | comments 0


Engineered cytomegalovirus protects monkeys from HIV equivalent

(Medical Xpress)—A new study by researchers in the US has shown that an ancient virus can be modified to help in the fight against the simian immunodeficiency virus SIV, which is the equivalent in monkeys ...

Researchers identify first drug targets in childhood genetic tumor disorder

Two mutations central to the development of infantile myofibromatosis (IM)—a disorder characterized by multiple tumors involving the skin, bone, and soft tissue—may provide new therapeutic targets, according to researchers ...

Hormone levels may provide key to understanding psychological disorders in women

Women at a particular stage in their monthly menstrual cycle may be more vulnerable to some of the psychological side-effects associated with stressful experiences, according to a study from UCL.

Going live: Immune cell activation in multiple sclerosis

Biological processes are generally based on events at the molecular and cellular level. To understand what happens in the course of infections, diseases or normal bodily functions, scientists would need to ...

Help at hand for people with schizophrenia

How can healthy people who hear voices help schizophrenics? Finding the answer for this is at the centre of research conducted at the University of Bergen.

Alzheimer's disease, the soft target of the euthanasia debate

(Medical Xpress)—The way Alzheimer's disease is portrayed by advocacy groups and the media is having undue influence on the euthanasia debate, according to a Deakin University nursing ethics professor.